Trial to Investigate the Use of Cannabidiol to Treat Psychosis Induced by Parkinson’s

October 17, 2019 08:00:20

CBD has built quite a reputation in the few years it has been mainstream. The list of diseases CBD has in the past proven effective against spans from minor conditions such as anxiety and inflammation to severe ones like chronic pain and epilepsy. At this point, it’s anyone’s guess what else cannabidiol works against.

A new clinical trial will investigate the efficacy of CBD on patients who have Parkinson’s induced psychosis. Parkinson’s UK, in partnership with scientists at King’s College London, will lead the study, and it has invested €1.2 million ($1.3 million) in a Phase 2 clinical trial. Parkinson’s UK is the largest charitable funder of…


About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office